每日市场观察 2025 年 7 月 16 日 【今日关注】 周二两市早盘冲高回落午后缓慢回升。截至收盘，沪指跌 0.42%，深成 指涨 0.56%，创业板指数涨 1.73%。板块方面，互联网服务、游戏、软 件开发、通信设备、汽车整车、电源设备等涨幅居前；珠宝首饰、煤 炭、电力、采掘、能源金属、光伏设备等板块调整明显。两市跌多涨 少，其中上涨股票 1287 只，下跌股票数量 3872 只；沪深两市总成交 金额超 1.61 万亿，环比有所放大。 当下市场处于行情启动初期，其特征是股指慢涨急跌，权重股震荡向 上打开空间，并利用快速调整吸引投资者换筹提高持仓成本。如果投 资者持有的不是主流品种，就会陷于"赚了指数不赚钱"的境地。因 此在策略上，要么在回调中切换权重红利股，要么坚定持有优质品种 等待后面的普涨，切忌随意调仓。 在行情启动初期，权重板块是向上拓展空间的主力，它们上攻时间越 长，股指上涨的空间就越大，因此当下的调整空间和时间较为有限。 投资者切忌追涨杀跌增加持仓成本，可耐心等待调整结束后逢低吸纳 权重股、"中字头"、红利股或红利 ETF 等待涨。在市场调整中，部 分资金会流向人气题材股，生物医药、芯片、人工 ...

2025 年 7 月 15 日，西湖大学 何丹阳 课题组与 徐和平 课题组合作 （ 王琰 为第一作者 ） ， 在 Immunity 期刊 发表题为： Cognate interaction-dependent pathogenicity of meningeal B cells drives neuroinflammation relapse 的研究论文。 该研究表明， 脑膜内自身反应性 B 细胞与抗原特异性 T 细胞相互作用，促进神经系统自身免疫性炎症的 复发 ，首次证实了中枢神经系统局部 B 细胞是神经炎症复发的关键开关，也为多发性硬化症 （MS） 的"中枢炎症驱动"理论提供了直接证据。 撰文丨王聪 编辑丨王多鱼 排版丨水成文 B 细胞 是中枢神经系统 （CNS） 自身免疫疾病 的核心驱动因素，例如 多发性硬化症 （ Multiple Sclerosis， MS） 。尽管 脑膜 通常维持着严格不发生自身免疫反应的 B 细胞谱系，但这种局部免疫耐受 的破坏如何导致病理变化，目前仍不清楚。 在这项最新研究中，研究团队证明了位于大脑边缘的自身反应性 B 细胞通过直接与致脑炎性 T 细胞结合而 加速了神经炎症。 ...

日经GO 日本研究发现可增强癌症免疫药效果的肠道细菌 原创 阅读全文 ...

国家统计局7月15日发布的数据显示，6月份，社会消费品零售总额为4.2万亿元，同比增长4.8%。 上半年，社会消费品零售总额为24.5万亿元，同比增长5.0%。国家统计局副局长表示，我国正处在消费 结构升级的关键阶段，人均GDP连续两年稳定在1.3万美元以上，文化旅游、医疗健康、养老消费空间 广阔，我国市场规模优势非常明显。中国未来的消费成长性非常好，市场空间非常广阔。 7月16日，港股三大指数集体高开，恒指涨0.46%，国指涨0.56%，恒生科技指数涨0.89%。盘面 上，大型科技股全线上涨，生物医药股继续上扬，创新药概念股活跃，稀土概念股走高，新消费概念股 多数上涨，港股消费板块走势强劲，港股消费ETF（513230）现涨近2.5%。 港股消费ETF（513230）一键网罗港股新消费龙头。 每日经济新闻 （责任编辑：张晓波 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 平安证券研报称，紧抓精神需 ...

消息面上，7月15日夜盘纳指带动中概股大涨。推动纳指上涨的主要动力来自英伟达，该股当日上涨4%，最新市值约4.17万亿美元，其市值一夜增加1618亿 美元（约合人民币11605亿元）。此前，英伟达在官网发文称，公司将恢复H20在中国的销售。 对于港股科技感兴趣的投资者可以关注港股科技ETF（513020）布局机会，没有股票账户的投资者可以关注港股科技ETF联接基金（联接 A：015739；联接 C：015740）。 当前港股科技板块正处于"估值洼地"与"产业变革"的交汇点，政策、技术、资金三因素共振推动配置价值显著提升。资金面上，南向资金与外资形成合力， 持续改善板块流动性；政策面上，产业支持与资本市场改革双重利好叠加，从盈利基础与估值体系双维度提振市场信心。从盈利端来看，彭博一致预期显示 2025年-2027年恒生科技指数EPS将保持逐年上行趋势，叠加当前板块估值仍处历史低位，有望迎来"估值修复"与"盈利增长"的戴维斯双击行情。在AI技术迭 代、政策环境优化及全球资金再配置的驱动下，港股科技板块或将成为新一轮市场行情的重要引擎。 港股科技ETF（513020）紧密跟踪中证港股通科技指数，该指数精选通过港股通 ...

Group 1 - A total of 1525 A-share listed companies disclosed their mid-year performance forecasts, with 662 companies expecting positive growth, representing 43.41% of the total [2] - The industries showing strong performance include biomedicine, basic chemicals, artificial intelligence, semiconductors, rare earths, gold, and securities [2] - 869 companies are expected to see a year-on-year net profit increase, with 428 companies forecasting over 100% growth [3] Group 2 - China Shenhua is projected to have the highest net profit at 25.6 billion yuan, followed by Zijin Mining and Guotai Junan with 23.2 billion yuan and 19.557 billion yuan respectively [3][4] - Companies like Lixun Precision and Xinyisheng are experiencing significant growth due to their strategic positioning and market demand, particularly in high-end manufacturing and AI-related investments [4] - Some companies have seen their stock prices surge significantly following positive earnings forecasts, with Huayin Power's stock hitting the limit up six times in seven days [5] Group 3 - Analysts predict an overall improvement in A-share performance in the second half of the year, driven by a moderate recovery in the macro economy and sustained high demand in sectors like electronics and communications [5] - The focus on expanding domestic demand is expected to benefit leading companies in consumer sectors such as automotive and home appliances [5]

Core Viewpoint - Ma'anshan is positioning itself as a key city in the Yangtze River Delta, focusing on the development of new quality productive forces and a modern industrial system that integrates traditional industries, emerging industries, future industries, and modern services [1][5][11]. Group 1: Economic Performance - In 2024, Ma'anshan's GDP is projected to reach 278.46 billion yuan, with a growth rate of 6.0% compared to the previous year [5]. - The primary industry added value is 11.4 billion yuan (3.5% growth), the secondary industry 120.93 billion yuan (6.6% growth), and the tertiary industry 146.13 billion yuan (5.7% growth) [5]. - The industrial added value is expected to be 87.92 billion yuan, also growing by 6.0% [5]. Group 2: New Quality Productive Forces Overview - New quality productive forces emphasize innovation as the main driving force, characterized by high technology, efficiency, and quality, aligning with new development concepts [2][3]. - This concept is crucial for promoting high-quality economic development and constructing a modern industrial system [3]. Group 3: Modern Industrial System - Ma'anshan is building a modern industrial system based on "four-dimensional driving and tiered development," focusing on traditional industry upgrades, emerging industry clusters, future industry layouts, and modern service enhancements [1][17]. - The strategy includes transforming traditional industries like steel and machinery through intelligent upgrades and promoting new industries such as intelligent equipment and high-end CNC machine tools [17]. Group 4: Key Industries and Companies - Key industries in Ma'anshan include steel, new materials, new energy vehicles, high-end equipment manufacturing, biomedicine, and digital economy [23]. - Representative companies include Ma'anshan Iron and Steel Co., Ltd., Hanma Technology, and East China Semiconductor, which are leading in their respective fields [23][24]. Group 5: Policy Background and Support - The concept of new quality productive forces was included in the government work report for the first time in 2024, emphasizing innovation and the transition from traditional economic growth models [11]. - Ma'anshan has implemented various policies to support the development of new quality productive forces, including digital empowerment and the cultivation of strategic industry clusters [11][14]. Group 6: Development Trends - The city is advancing traditional industry upgrades alongside the rise of emerging industries, with a focus on technological innovation [26][27]. - Future industries are being actively developed, with a focus on advanced materials, general intelligence, and low-carbon energy [28]. - The innovation ecosystem is being optimized, with a strong emphasis on talent support and collaboration between industry and academia [29].

Group 1 - The 14th China Innovation and Entrepreneurship Competition in Zhengzhou successfully held its finals, featuring 11 projects from the growth group and 5 from the startup group advancing to the provincial competition [1] - The competition focused on key areas such as intelligent manufacturing, green low-carbon initiatives, and modern agriculture, covering strategic emerging industries like new-generation information technology, high-end equipment manufacturing, and biomedicine [1] - Zhengzhou aims to implement major requirements for innovation and entrepreneurship, striving to become a leading city in technological innovation within the province [1] Group 2 - The China Innovation and Entrepreneurship Competition is an annual event that gathers numerous entrepreneurial elites, scholars, and entrepreneurs, having successfully nurtured star companies like Zhongke Qingneng and Lingxi Biology [2] - The current competition emphasizes service innovation, providing one-stop services such as pre- and post-competition guidance and investment financing connections to enhance the competition's soft power [2] - Zhengzhou is committed to creating a top-tier ecosystem that encourages innovation, supports entrepreneurship, and helps participants achieve success, thereby empowering business development [2]

Group 1: Economic Development and Industry Highlights - Heze has positioned itself as a hub for unique industries, focusing on the development of specialty industries such as the peony industry, high-end chemical industry, and biomedicine [2][3] - The peony industry in Heze is the largest in the world, with over 1,308 varieties cultivated and a total output value of 13 billion yuan in the previous year [2] - The sheep soup industry in Shan County has achieved a total industry chain output value exceeding 16 billion yuan, with a public brand value of 36.6 billion yuan [3] Group 2: Innovation and Talent Development - Heze is fostering innovation through the establishment of platforms that attract talent and support technological advancements, exemplified by the creation of an intelligent flexible shared industrial platform [3][4] - The collaboration between local companies and academic institutions has led to significant advancements, such as the development of a 20-micron ultra-thin conductive fabric with a market share exceeding 30% [4] Group 3: Urban Management and Quality of Life - Heze has been recognized as a national civilized city, reflecting its commitment to improving urban management and addressing public concerns [4][6] - The city has implemented innovative solutions for parking challenges, including the "Heze Smart Parking" app, enhancing the overall living environment for residents [5][6]

Core Viewpoint - The article highlights the success story of Yang Xia, the founder of Jinbo Biological, who transformed a small startup with 500,000 yuan into a leading biological materials company valued at over 20 billion yuan, focusing on human-derived collagen protein for the medical aesthetics industry and beyond [4][6]. Company Overview - Jinbo Biological was established in 2008 with a mission to develop recombinant human-derived collagen protein, addressing a significant gap in the market due to the high costs and limitations of natural collagen [5][6]. - The company achieved a major breakthrough in 2014 by successfully developing the first recombinant type III collagen product, leading to the establishment of the world's first production line for recombinant human-derived collagen in 2019 [6][7]. Financial Performance - Jinbo Biological went public on the Beijing Stock Exchange on July 20, 2023, with an initial stock price of 49 yuan, raising 245 million yuan. The company's market capitalization reached 12 billion yuan on its first trading day [7]. - In 2024, the company reported a revenue of 1.443 billion yuan, a sixfold increase over three years, with a net profit of 732 million yuan, reflecting a year-on-year growth of 144.3% [7][11]. Product Development - The core product, "Wei Yimei," contributed 1.254 billion yuan to the revenue, accounting for 86.89% of total sales, and is used in over 4,000 medical institutions across China [7][11]. - Jinbo Biological has received three Class III medical device certifications for its recombinant collagen injection products, establishing a strong technical barrier in the industry [8][10]. Strategic Partnerships and Investments - In 2025, Jinbo Biological announced a significant capital operation, raising 2 billion yuan through a private placement to expand production capacity and develop a collagen protein database [9]. - The company also entered into a strategic partnership with Zhong Shanshan, acquiring a 10.58% stake, which aims to leverage distribution channels for functional foods and skincare products [9][10]. Future Outlook - Jinbo Biological is expanding its applications of collagen protein beyond medical aesthetics into fields such as gynecology and orthopedics, emphasizing the material's potential as a life material [11][12]. - The company is also focusing on maintaining its competitive edge through original innovation and establishing a functional protein research institute to foster long-term technological development [11][12].